{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-23-000077","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.603402+00:00","generated_at":"2026-06-13T17:12:33.716165+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio preclinical data show FRα-CoStAR enhances TIL activity; clinical restart H2 2023","bullets":["Oral presentation at BSGCT conference on ITIL-306 preclinical data.","FRα-CoStAR enhanced TIL activity against autologous NSCLC, ovarian, and renal tumors.","Enhanced activity exceeded melanoma TILs as measured by IFNγ secretion.","ITIL-306 clinical study anticipated to resume in 2H 2023; initial clinical data expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-23-000077","json":"https://secwatch.observer/filing/0001789769-23-000077.json","markdown":"https://secwatch.observer/filing/0001789769-23-000077.md","text":"https://secwatch.observer/filing/0001789769-23-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000077/0001789769-23-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000077/til-20230626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:12:33.716165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}